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Introduction: The Italian Association of Medical Oncology and the 
Italian Society of Anatomic Pathology and Diagnostic Cytopathology 
organized an external quality assessment (EQA) scheme for anaplastic 
lymphoma kinase (ALK) rearrangement by florescence in situ hybrid-
ization (FISH) analysis in non–small-cell lung cancer (NSCLC).
Methods: Sections from tissue microarrays, each including 10 
NSCLC samples with known ALK status, were first validated in five 
referral laboratories and then provided to 37 participating centers. 
The laboratories were requested to perform the FISH test, using their 
usual protocols, and to complete the analysis within 3 weeks. By 
using a predefined scoring system, two points were assigned in case 
of correct genotype and zero points to false-negative or false-positive 
results. The threshold value to pass the EQA scheme was set at 18 
points. Two rounds were planned.
Results: Thirty-four centers submitted the results within the estab-
lished deadline. Several errors in the evaluation of genotype (n = 
18) were reported, with both false-positive (n = 7) and false-negative 
(n = 11) results. Test failure occurred in seven cases. Two samples 
were found to be critical by two referral laboratories and seven partic-
ipating centers. Twenty-six (70%) laboratories passed the first round 
and six the second round. Overall, 32 (86%) laboratories passed the 
ALK EQA scheme.
Conclusions: The results of this first EQA scheme for ALK testing in 
NSCLC cancer patients indicate that ALK analysis is performed with 
adequate quality in most Italian laboratories and highlight the impor-
tance of EQA in revealing methodological problems that need to be 
addressed to further increase the reproducibility of molecular tests.
Key Words: Non–small-cell lung cancer, ALK rearrangement, FISH, 
Quality assessment.
(J Thorac Oncol. 2014;9: 1470–1476)
Genetic aberrations that drive human malignancies, known as driver mutations, can be used as therapeutic targets 
for specific drugs. In patients with non–small-cell lung can-
cer (NSCLC) and epidermal growth factor receptor (EGFR)-
sensitizing mutations, EGFR tyrosine kinase inhibitors such 
as gefitinib or erlotinib induced dramatic tumor responses and 
improved survival.1–3 More recently, similarly remarkable out-
comes have been reported in lung cancer patients with ALK 
gene rearrangement who underwent a crizotinib-based treat-
ment (PF-02341066 Pfizer).4
Chromosomic rearrangements involving the anaplastic 
lymphoma kinase (ALK) gene were first identified as onco-
genic events in anaplastic large-cell lymphomas in 1994.5 More 
recently, an inversion event on the short arm of chromosome 2, 
resulting in the fusion of ALK gene with the EML4 gene locus, 
was identified as the most common ALK aberration in NSCLC 
patients. The chimeric protein (EML4-ALK) resulting from 
this rearrangement confers a strong proliferative stimulus to 
the neoplastic cells.6,7 More than 10 EML4-ALK fusion vari-
ants with transforming activity in vitro have so far been identi-
fied in lung cancer patients.8,9 Other fusion patterns including 
tyrosine receptor kinase (TRK)-fused gene and kinesin family 
member 5B (KIF5B)10 have been reported, but clinical data for 
patients harboring these variants are very limited.
In unselected patients with NSCLC, the prevalence of 
ALK rearrangement ranges from 1% to 7%,6 depending on 
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the population studied and the ALK detection methods used. 
However, a prevalence of more than 30% has been observed 
in patients with EGFR and KRAS wild-type, adenocarcinoma 
histology and absent or light smoking history.11 This is consis-
tent with the notion that ALK rearrangement defines a unique 
molecular subset of NSCLC, with distinct clinical and patho-
logic characteristics. Indeed, patients who most likely harbor 
EML4-ALK translocation tend to be younger, never/light 
smokers with lung adenocarcinoma.
Phase 1 and 2 clinical studies have shown that crizotinib 
is active in patients with advanced, ALK-positive NSCLC.12–14 
These data led to the accelerated approval of crizotinib by 
the U.S. Food and Drug Administration (FDA) in August 
2011.15 The use of the drug has been restricted to patients 
with advanced, ALK-positive NSCLC evaluated by an FDA-
approved test, the Vysis ALK Break Apart florescence in situ 
hybridization (FISH) Probe Kit, that has become the gold stan-
dard for detecting ALK rearrangement in NSCLC.16 In October 
2012, the European Medicine Agency granted conditional mar-
keting authorization in the European Union for crizotinib for 
the treatment of patients with previously treated ALK-positive, 
advanced NSCLC. Following this conditional approval, ALK 
testing has become mandatory to select patients to be treated.
In Italy, recommendations for ALK rearrangement analy-
sis were elaborated in 2012 by a steering committee of members 
of the Italian Association of Medical Oncology (AIOM) and 
the Italian Society of Pathology and Cytopathology (SIAPEC-
IAP).17 Following the publication of the guidelines, the AIOM-
SIAPEC societies started an educational program, presenting and 
discussing the recommendations at national meetings. Moreover, 
an external quality assessment (EQA) scheme for ALK test-
ing was organized to evaluate the effects of recommendations 
on molecular diagnostics in Italy and establish interlaboratory 
consistency, with the aim of improving the qualitative standard 
for this analysis and allowing an appropriate NSCLC patient 
selection for treatment with crizotinib. This article describes the 
development and the results of the first Italian EQA scheme for 
ALK testing, which was completed in March 2013.
MATERIALS AND METHODS
Organization of the Scheme
AIOM and SIAPEC identified a board of Italian pathol-
ogists and oncologists with particular experience in lung can-
cer who were assigned to organize the EQA scheme and that 
are coauthors of this document. Within the team, five surgical 
pathology departments (Department of Pathology, University-
Foundation, Chieti, Italy; Division of Pathology and 
Laboratory Medicine, European Institute of Oncology, Milan, 
Italy; Division of Anatomic Pathology, San Luigi Hospital 
and University of Turin, Orbassano, Italy; Diagnostic and 
Laboratory Medicine, National Cancer Institute “Fondazione 
Pascale,” Naples, Italy; Pathology Department, Policlinico of 
Modena, Italy) were identified as referral centers of the EQA 
program for ALK testing. They were in charge of selecting 
and validating the samples for the EQA.
AIOM and SIAPEC decided to conduct the EQA 
scheme for ALK rearrangement by FISH analysis, as this is 
currently the method of choice for ALK assessment following 
the results obtained in clinical trials which led to the approval 
of crizotinib for treatment of NSCLC patients. However, a spe-
cific kit was not recommended, since the European Medicine 
Agency does not demand for a particular one.
The scheme included two rounds: the laboratories which 
failed the first round had the chance to register for a second round.
Selection and Validation of Samples
In the five referral centers, a series of 30 resected forma-
lin-fixed paraffin-embedded (FFPE) NSCLC specimens were 
selected from a large cohort of more than 1000 consecutive 
FIGURE 1.  Example of a tumor sample (A) 
in which areas with the highest percentage of 
tumor cells immunoreactive with the anti-
ALK D5F3 monoclonal antibody (magnified 
in B) and positive by FISH analysis (C) were 
selected for TMA construction. ALK, anaplastic 
lymphoma kinase; FISH, fluorescence in situ 
hybridization; TMA, tissue microarray.
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patients affected by NSCLC underwent to radical resection of the 
primary tumor. Twenty out of the 30 selected samples harbored 
ALK rearrangement by FISH. Samples with ALK rearrange-
ment were also subjected to immunohistochemical analysis for 
ALK protein expression using the D5F3 monoclonal antibody 
(Cell Signaling Technology, Beverly, MA) that confirmed an 
alteration of ALK in all cases. Ten FFPE specimens (six negative 
and four positive for ALK rearrangement) were further selected 
on the bases of the thickness of the tissues available, the content 
of ALK-positive tumor cells, and the pattern of ALK alteration 
(split signal, single orange signal). After careful histological 
revision of the selected samples, areas with the highest percent-
age of tumor cells positive by FISH analysis and reacting with 
ALK D5F3 monoclonal antibody were selected for tissue micro-
arrays (TMAs) construction (Fig. 1). The construction of a series 
of TMAs was performed at the Center of Predictive Molecular 
Medicine, University of Chieti. Selected neoplastic areas were 
withdrawn with a 2-mm puncher (mta1 Beecher Instruments, 
Sun Prairie, WI) and assembled in a 10-core TMA (one core 
per sample) (Fig. 2). Then, from each TMA paraffin block, one 
5-μm-thick blank histological section was sent to the five referral 
surgical pathology laboratories for ALK testing by FISH. All the 
centers used the Vysis ALK Break Apart Rearrangement Probe 
(Abbott Diagnostics, Abbott Park, IL), but the prehybridization 
protocol was not the same in all referral laboratories.
Registration of the Participants 
and Shipment of the Samples
Italian laboratories that performed FISH analysis for 
diagnostic evaluation of ALK rearrangement in NSCLC 
patients were invited to join the EQA scheme. Participating 
laboratories, registered at the http://www.alkquality.it Web 
site, were requested to perform FISH analysis using their 
usual method. A 5-μm-thick TMA slide was sent to each of the 
registered laboratories. Before sending the sections, the first, 
twentieth, and last sections obtained from TMA blocks were 
subjected to FISH analysis at the Referral Center of Chieti to 
confirm the results previously obtained. The characteristics of 
the four positive sample on the last section are summarized in 
Table 1. All positive samples showed a high percentage of cells 
with ALK rearrangement, two samples showed a high per-
centage of single red signals, and two samples a high percent-
age of split signals. Random codes, different for each center, 
were automatically assigned to the samples by an application 
of the Web site to avoid exchange of information among the 
participants. The laboratories were given 3 weeks to complete 
the analysis and submit the results through the ALK quality 
Web site. The centers were asked to define cases as positive, 
negative, or not assessable according to the criteria reported in 
the Italian Recommendation for ALK gene rearrangement.17 
Information on the number and percentage of positive nuclei 
was not requested. The centers were also demanded to provide 
information about the type of probe and prehybridization type 
used. Samples for the first and the second round were sent on 
December 12, 2012, and on February 28, 2013, respectively.
Evaluation of the Results
The AIOM/SIAPEC board of assessors evaluated 
the results using a scoring system, in agreement with the 
European guidelines for EQA in molecular pathology.18 The 
scoring system assigned two points in case of accurate evalu-
ation of genotype and zero points to false-negative or false-
positive results. The threshold value to pass the EQA scheme 
was set at 18 points. In case of an analytical error (test failure 
with no result on the sample), one point was assigned for the 
first error, and zero from the second onward.
FIGURE 2.  Example of a tissue microarray used in the ALK 
EQA scheme: A, paraffin block; B, section stained with hema-
toxylin and eosin showing the good quality of 2 mm cores; 
C, scheme of the distribution of ALK-positive (P) and ALK-
negative (N) cases in this particular microarray. ALK, anaplas-
tic lymphoma kinase; EQA, external quality assessment.
TABLE 1.  FISH Analysis of the Four Samples Carrying ALK 
Alterations
ALK-Positive  
Cores
Cells with ALK 
Alterations
Predominant  
Alteration
Core 4 60% Split signal (90%)
Core 5 65% Single red signal (95%)
Core 6 80% Single red signal (95%)
Core 8 90% Split signal (90%)
FISH, fluorescence in situ hybridization; ALK, anaplastic lymphoma kinase.
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Statistical Analysis
The variables measured in the study were investigated 
for association by using the Fisher’s exact test or chi-square 
test as appropriate. A p value less than 0.05 was considered as 
significant. All statistical analyses were performed using the 
SPSS pack (version 15; SPSS, Chicago, IL).
RESULTS
Validation of the Samples for the EQA 
Scheme in the Referral Centers
A high degree of concordance was obtained by FISH 
analysis on sections from TMAs in the five referral centers 
(Table 2). However, in two centers two cases (case n. 2 and 
case n. 9) were judged as not assessable due to lack of probe 
signal. These samples were considered as “critical or bor-
derline cases.” Nevertheless, it was decided to include them 
in the EQA scheme, with the aim of pointing out possible 
latent weaknesses in test performance and interpretation 
of the results. Obviously, where an approach as this is fol-
lowed, more laboratories might fail. Therefore, as suggested 
in the recent guidelines on the requirements of EQA pro-
grams in molecular pathology, we decided not to consider 
as failure the inability to evaluate the two critical cases. Test 
failure in these cases has been reported as not assessable in 
critical sample.
First Round
Thirty-seven laboratories registered to the Italian ALK 
EQA scheme. Thirty-four participating centers submitted the 
results within the established deadline. Overall, 26 (70%) lab-
oratories passed the first round, having reached a score of 18 
points or greater (Fig. 3).
Several errors in the evaluation of genotype (n = 18) 
were found, with both false-positive (n = 7) and false-nega-
tive (n = 11) results. Moreover, test failure in suitable sample 
occurred in seven cases (reported as not assessable in suitable 
sample) (see Table 3). The errors (false positive/false positive) 
reported were randomly distributed in the different cores of the 
TMA. However, six of the 34 centers (18%) failed on sample 
N.5 (Table 4). Three (50%) of the laboratories that failed with 
sample N.5 made errors on other cores. This relatively difficult 
sample, re-evaluated at the Referral Center of Chieti on the 
last TMA section (see Materials and Methods), showed 65% 
of rearranged nuclei (95% with single red signals) (Table 1).
Second Round
The 11 centers that did not pass the first round were 
given information about the number and type of errors made, 
but they were not informed on the results of the specific 
samples previously analyzed. Subsequently, according to the 
guidelines of the scheme, the 11 centers were invited to partic-
ipate in a second round. TMAs with the same samples, but dif-
ferently arranged and provided of code number different from 
the one given in the first round, were sent to the laboratories.
Five centers did not pass the second round: three labo-
ratories did not submit the results within the established dead-
line (same centers that did not submit data in the first round), 
and two laboratories once again scored below 18. Of these 
two latter laboratories, one reported errors in the evaluation of 
genotype (both false-positive and false-negative results), and 
the other one did not get probe signals on the samples (com-
plete test failure) (Table 5).
Overall, 32 out of 37 Italian laboratories (86%) passed 
the ALK EQA scheme, having reached a score of 18 points or 
higher in the first or in the second round of the EQA (Fig. 3). 
The list of the centers that passed the EQA has been published 
on the AIOM and SIAPEC Web sites (http://www.aiom.it; 
http://www.siapec.it).
Several commercial kits are available to evaluate ALK 
rearrangements by FISH. In Table 6, the performance of the 
different commercial tests used by the laboratories participat-
ing in the first round of the EQA scheme are reported. For 
each test, the number and percentage of the correct genotypes 
and the different type of errors are indicated. Of the 34 centers 
that submitted data, 25 (74%) utilized the FDA-approved LSI 
Vysis ALK Break Apart FISH Probe Kit (Abbott Diagnostics), 
4 the ALK FISH DNA Probe, Dako (Via Real Carpinteria, 
CA), 3 the ZytoLight SPEC ALK/EML4 TriCheck Probe, 
ZytoVision (Bremerhaven, Germany), and 2 the ON ALK 
TABLE 2.  Results Obtained by the Five Referral Centers in the Validation Study
Center Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10
1 N N N P P P N P N N
2 N N N P P P N P N N
3 N N N P P P N P N N
4 N NA N P P P N P NA N
5 N NA N P P P N P NA N
N, negative; P, positive; NA, not assessable.
FIGURE 3.  Results of the first Italian external quality assess-
ment for ALK testing. ALK, anaplastic lymphoma kinase.
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(2p23) Break, Kreatech (Amsterdam, The Netherlands). Due 
to the low number of laboratories that used commercial kits 
different from the ALK breakApart test, the power of a statis-
tical comparison among the various kits utilized is very lim-
ited. No significant differences were observed.
Regarding the two cases considered as critical, seven 
of the 32 centers (22%) that passed the EQA scheme defined 
these samples as not assessable. An accurate analysis of the data 
obtained during the validation of the samples by the five referral 
laboratories indicated that the inability to evaluate the critical 
cases was related to differences in the prehybridization step.
DISCUSSION
Molecular testing of biological specimens to guide 
therapeutic protocols is of increasing relevance. In the last 
decade, several drugs have been approved for the treatment 
of specific subgroups of patients having tumors harboring dis-
tinct molecular alterations. In the European Union, the ALK 
inhibitor crizotinib has recently received conditional market-
ing authorization for treatment of patients with previously 
treated ALK-positive advanced NSCLC. After this approval, 
the accurate detection of ALK rearrangement has become 
mandatory, as the result of such testing is key to manage ther-
apy, with both false-negative and false-positive results being 
harmful for patients.
The Italian health system is structured on a regional 
basis, and there is no limit in the number of laboratories 
that can perform molecular analyses, with few exceptions in 
restricted geographical areas. When crizotinib was approved, 
several centers were offering ALK testing in different areas 
of the country. Since in Italy there is no national or regional 
health authority that releases guidelines or organizes EQA 
TABLE 3.  Results of the First Round of the Italian EQA 
Scheme for ALK Rearrangement Testing in NSCLC Samples
Center Outcome Type of Error
1 Passed 1FP
2 Not passed 3FP + 1NASS
3 Passed
4 Passed
5 Not passed 2FP
6 Passed
7 Not passed 1FN + 2NASS
8 Not passed Data not submitted
9 Not passed Data not submitted
10 Passed
11 Not passed 1FN + 1NASS
12 Passed
13 Passed 1NASS
14 Passed
15 Passed
16 Passed
17 Passed
18 Passed
19 Passed
20 Passed
21 Passed
22 Passed
23 Passed
24 Passed 1NACS
25 Passed 2NACS
26 Passed 1FN + 1NACS
27 Passed 1FN + 2NACS
28 Passed 1FN + 2NACS
29 Not passed 2NASS
30 Not passed 2FN
31 Not passed 2FN + 2NACS
32 Not passed 1FP + 1FN
33 Passed 1FN
34 Passed
35 Passed 1NACS
36 Passed
37 Not passed Data not submitted
EQA, external quality assessment; ALK, anaplastic lymphoma kinase; NSCLC, 
non–small-cell lung cancer; FP, false positive; FN, false negative; NACS, not assessed in 
critical sample; NASS, not assessed in suitable sample.
TABLE 5.  Results of the Second Round of the Italian EQA 
Scheme for ALK Rearrangement Testing in NSCLC Samples
Center Outcome Type of Error
1 Not passed Data not submitted
2 Not passed Data not submitted
3 Passed
4 Not passed Complete test failure
5 Passed
6 Passed
7 Not passed Data not submitted
8 Passed
9 Passed
10 Passed
11 Not passed 1 FN and 3 FP
EQA, external quality assessment; ALK, anaplastic lymphoma kinase; NSCLC, 
non–small-cell lung cancer; FP, false positive; FN, false negative.
TABLE 4.  Number of Errors (FP/FN) per TMA Core
TMA Core Number Errors (N)
Core 1 (wild type) FP (1)
Core 2 (wild type) FP (1)
Core 3 (wild type) FP (1)
Core 4 (ALK rearrangement) FN (2)
Core 5 (ALK rearrangement) FN (6a)
Core 6 (ALK rearrangement) FN (1)
Core 7 (wild type) FP (1)
Core 8 (ALK rearrangement) FN (2)
Core 9 (wild type) FP (2)
Core 10 (wild type) FP (1)
aThree of the six centers made errors in other cores (core 5 + core 3; core 5 + core 
4; core 5 + core 1).
FP, false positive; FN, false negative; TMA, tissue microarray; ALK, anaplastic 
lymphoma kinase.
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programs for molecular pathology, AIOM and SIAPEC 
decided to launch a program to improve ALK testing in the 
country. The program comprised the publication of guidelines, 
the development of training courses, and the organization of 
an EQA scheme to ensure that ALK testing is performed with 
high quality in every Italian center that provides this service.
Different methods are available for the analysis of ALK 
rearrangement, and each of them has advantages and disad-
vantages. The European regulatory agency has not linked 
the authorization of crizotinib to a specific type of analysis, 
whereas the FDA restricted the use of the drug to detection 
by FISH. The Italian EQA scheme was based on FISH test-
ing, as this is widely considered the elective method for ALK 
assessment. This method can be performed on FFPE samples 
and was used in the clinical trials which led to the approval 
of crizotinib for treatment of NSCLC patients. However, a 
specific kit was not recommended, since the EMA does not 
demand for a particular one.
The main purpose of the EQA scheme for the detec-
tion of ALK rearrangements in NSCLC patients promoted by 
AIOM and SIAPEC was to assess the rate of analytical errors. 
Laboratories were neither required to indicate the percentage 
of neoplastic cells nor the percentage of tumor cells with rear-
rangement. Therefore, samples for the analysis were selected 
on the basis of a high percentage of tumor cells and a diffusely 
rearranged ALK genotype.
Different types of samples can be used for EQA. For the 
specific purpose of this investigation, we decided to gener-
ate TMAs with 2 mm cores containing a total of 10 samples 
which has been suggested as the adequate number of cases 
for a proficiency testing.19 Since the great majority (approxi-
mately 70%) of lung cancer patients present in an advanced 
stage of disease, in most cases no resection specimens are 
available and only tissues collected at the initial diagnostic 
work-up can be used for histopathological diagnosis of lung 
cancer and subsequent molecular analyses. Hence, the use of 
small tissue specimens in an EQA scheme can better mimic 
the routine clinical activity. However, we believe that the use 
of TMA cores smaller than 2 mm is not practical, since core 
sections are more prone to detach from the slide. Another char-
acteristic of the samples used in this EQA which guarantees 
the similarity with the daily clinical practice is the different 
source of the specimens, as the ten samples came from five 
different surgical pathology departments.
Overall, the results of this EQA suggest that ALK test-
ing is performed with adequate quality in the majority of 
Italian centers, in that 32 (86%) out of 37 laboratories passed 
the EQA. However, this conclusion may be limited by the type 
of samples used which had a very high percentage of tumor 
cells. Nevertheless, we noticed a high number of analytical 
errors. In the first round, 12 laboratories reported at least one 
false-positive or false-negative result. Both these results are 
detrimental for NSCLC patients, causing the application of 
inadequate treatment protocols.
False-positive results might be caused by prehybrid-
ization issues. If pretreatment of the tissue is inadequate, the 
hybridization reaction could occur in an improper way, result-
ing in a weak or an absent probe signal. This could particularly 
affect green signals, as for this probe the signal–noise ratio is 
usually lower than that obtained with the orange one because 
of the high background fluorescence typically emitted by 
lung tissue. In these conditions, nuclei with an orange signal 
without a corresponding green signal could be considered as 
rearranged.
The rate of false-negative results was higher when com-
pared with false-positive (11 versus 7). False-negative results 
might be caused by an incorrect probe signal evaluation. Cells 
are considered negative (non-rearranged) when orange and 
green signals are fused or adjacent and positive when signals 
are two or more signal diameter apart.17 The misinterpretation 
of the distance between probe signals could be the main cause 
of false-negative results.
The decision to admit the two critical cases emerged dur-
ing the sample validation step highlighting weaknesses in test 
performance. The analysis of data obtained by the five referral 
centers suggests that the prehybridization protocol is a critical 
step for the success of the reaction in borderline cases. As is 
well known, the specifications for fixation and handling of tis-
sue specimens could be slightly different among laboratories 
or even among tissues processed in the same laboratory. These 
variables can influence the analytical step, especially if tissues 
are not processed under optimal conditions with an appropriate 
TABLE 6.  Performance of the Different FISH Tests Used in the Italian EQA Scheme
Report
Commercial Kit
Total pVysisa Dakob Zytovisionc Kreatechd
Correct genotype 221 (88.4%) 36 (90%) 27 (90%) 20 (100%) 304 NS (0.45)
False positive 6 (2.4%) 0 (0%) 1 (3.3%) 0 (0%) 7 NS (0.67)
False negative 8 (3.2%) 3 (7.5%) 0 (0%) 0 (0%) 11 NS (0.26)
NASS 6 (2.4%) 1 (2.5%) 0 (0%) 0 (0%) 7 NS (0.74)
NACS 9 (3.6%) 0 (0%) 2 (6.6%) 0 (0%) 11 NS (0.36)
Total 250 40 30 20 340e
FISH, fluorescence in situ hybridization; EQA, external quality assessment; NASS, not assessable in suitable sample; NACS, not assessable in critical sample; NS, not significant.
aLSI Vysis ALK Break Apart FISH Probe Kit, (Abbott Diagnostics, Abbott Park, IL).
bALK FISH DNA Probe, Dako (Via Real Carpinteria, CA).
cZytoLight SPEC ALK/EML4 TriCheck Probe, ZytoVision (Bremerhaven, Germany).
dON ALK (2p23) Break, Kreatech (Amsterdam, The Netherlands).
eTen cases were sent on a tissue microarray to each center; three centers did not submit data.
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digestion pretreatment. To overcome this difficulty, several 
commercial kits have been developed for the pretreatment of 
specific type of tissue, but in particular cases it could be neces-
sary to make adjustments even to standardized protocols. When 
dealing with very small amount of tissue, however, it may not 
be possible to carry out several attempts. For this reason, every 
molecular laboratory should be able to perform an effective 
FISH assay for each sample to be analyzed, without wasting 
the precious tissue material. In future EQA schemes, the use 
of TMA sections containing different specimens, including 
critical samples, may allow to test the capability of each cen-
ter to evaluate differently processed tissues and provide useful 
information to overcome technical problems related to tissue 
characteristics and handling. In this respect, we are planning 
to organize a further ALK EQA scheme (scheduled to start 
in 2015) in which we will accurately select tissue samples for 
TMA construction and collect detailed information on the 
technical protocols used by the laboratories.
The list of the centers that passed the EQA is published 
on the Web sites of AIOM and SIAPEC (http://www.aiom.
it; http://www.siapec.it). The publication of this list offers to 
both patients and clinicians the opportunity to choose among 
a wide number of certified laboratories, which are located in 
different regions of the country and that are able to provide 
ALK FISH testing with an adequate quality.
CONCLUSION
In conclusion, the results of this first Italian EQA 
scheme for ALK testing in NSCLC cancer patients indicate 
that the evaluation of ALK rearrangement is performed with 
adequate quality in most of the Italian diagnostic centers. In 
addition, our data highlight the importance of EQA in reveal-
ing methodological problems that must be addressed to fur 
ther increase the reproducibility and accuracy of molecular 
tests. As for the other EQA programs previously activated 
for KRAS, EGFR, and BRAF testing in Italy,20,21 the success 
of the ALK EQA scheme might be in part attributable to the 
publication of specific recommendations and the develop-
ment of local educational programs.17 The activity of AIOM 
and SIAPEC in this field might represent a model for other 
national and international associations.
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